February 3rd 2022
An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.
The role of BRAF inhibitors and checkpoint inhibitors in differentiated thyroid cancer, and potential considerations for using BRAF inhibition as redifferentiation therapy.